Last reviewed · How we verify
PlaceboMNTX
PlaceboMNTX is a placebo formulation with no active pharmacological mechanism.
At a glance
| Generic name | PlaceboMNTX |
|---|---|
| Also known as | Sodium Chloride 0.9%, Methylnaltrexone, Relistor |
| Sponsor | Region Örebro County |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo product, PlaceboMNTX contains no active pharmaceutical ingredient and produces therapeutic effects solely through placebo mechanisms such as patient expectation and conditioning. It is used in clinical research and potentially in clinical practice contexts where placebo response is therapeutically relevant.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PlaceboMNTX CI brief — competitive landscape report
- PlaceboMNTX updates RSS · CI watch RSS
- Region Örebro County portfolio CI